Schrödinger, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 04, 2022 at 04:01 pm EDT
Share
Schrödinger, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 15.58 million compared to USD 5.79 million a year ago. Revenue was USD 48.66 million compared to USD 32.13 million a year ago. Net loss was USD 34.44 million compared to USD 0.029 million a year ago. Basic loss per share from continuing operations was USD 0.48.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
SCHRÖDINGER, INC. 
